KCO has received research support from Alexion (part of AstraZeneca), Viela Bio (part of Horizon Therapeutics), Cabaletta Bio, and argenx. KCO is a consultant and equity shareholder of Cabaletta Bio. KCO has served as consultant/advisor for Alexion and Roche. EEL receives research support from Genentech and has served as a consultant for Genentech, Janssen, TG Therapeutics, NGM Bio, EMD Serono, Genzyme, and Bristol Myers Squibb. JMT receives royalties from Alexion and is a consultant for Q32 Bio, a company developing complement inhibitors. He holds stock in and will receive royalty income from Q32 Bio. RJN has received consultancy fees from Alexion, argenx, CSL Behring, Grifols, Immunovant, Momenta (part of Janssen), Ra Pharmaceuticals (part of UCB), and Viela Bio. CFL may accrue revenue for a patent regarding aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica, and receives research support from the National MS Society, Biogen,